↓ Skip to main content

Cochrane Database of Systematic Reviews

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer

Overview of attention for article published in Cochrane database of systematic reviews, July 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
13 tweeters
facebook
2 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
158 Mendeley
Title
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer
Published in
Cochrane database of systematic reviews, July 2012
DOI 10.1002/14651858.cd008941.pub2
Pubmed ID
Authors

Anna Dorothea Wagner, Christoph Thomssen, Johannes Haerting, Susanne Unverzagt

Abstract

Vascular-endothelial-growth-factor (VEGF) is a key mediator of angiogenesis. VEGF-targeting therapies have shown significant benefits and been successfully integrated in routine clinical practice for other types of cancer, such as metastatic colorectal cancer. By contrast, individual trial results in metastatic breast cancer (MBC) are highly variable and their value is controversial.

Twitter Demographics

The data shown below were collected from the profiles of 13 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 158 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 1%
United Kingdom 1 <1%
Ireland 1 <1%
Canada 1 <1%
Unknown 153 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 30 19%
Researcher 23 15%
Student > Bachelor 17 11%
Student > Ph. D. Student 16 10%
Other 12 8%
Other 28 18%
Unknown 32 20%
Readers by discipline Count As %
Medicine and Dentistry 71 45%
Nursing and Health Professions 17 11%
Agricultural and Biological Sciences 12 8%
Biochemistry, Genetics and Molecular Biology 7 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 15 9%
Unknown 32 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2016.
All research outputs
#2,040,145
of 18,304,658 outputs
Outputs from Cochrane database of systematic reviews
#4,640
of 11,826 outputs
Outputs of similar age
#14,230
of 135,989 outputs
Outputs of similar age from Cochrane database of systematic reviews
#35
of 109 outputs
Altmetric has tracked 18,304,658 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,826 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.6. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 135,989 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.